Metastatic adenocarcinoma of unknown primary origin

被引:65
|
作者
Hammar, SP [1 ]
机构
[1] Special Diagnost Lab, Bremerton, WA 98310 USA
关键词
metastatic; adenocarcinomas; neoplasms; unknown origin; electron microscopy; immunohistochemistry;
D O I
10.1016/S0046-8177(98)90007-7
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Adenocarcinomas account for up to 60% of all metastatic neoplasms of unknown primary origin. In general, adenocarcinomas are the most difficult metastatic tumor to accurately identify the primary site. Some metastatic adenocarcinomas have distinctive histological features that allow for their site determination (eg colonic adenocarcinoma, bronchioloalveolar cell carcinoma), although the majority of metastatic adenocarcinomas have histological features that are not distinctive enough to allow for a specific diagnosis of their origin. For this reason, electron microscopy and immunohistochemistry have been used to help identify the exact type (origin) of metastatic adenocarcinomas. Relatively specific ultrastructural features used to diagnose metastatic adenocarcinomas of unknown primary origin include tubular myelin, intranuclear surfactant apoprotein tubular inclusions, Clara cell granules, uniform short microvilli with filamentous cores and core rootlets, Langerhans cells associated with neoplastic cells, cytoplasmic hyaline globules, lipid droplets, glycogen, and cytoplasmic crystals. Only a few of these ultrastructural features are absolutely specific. Relatively specific immunohistochemical tests used to diagnose metastatic adenocarcinomas of unknown primary origin include prostate-specific antigen, thyroglobulin, estrogen and progesterone receptor proteins, thyroid transcription factor-I, and surfactant apoproteins. Of these, prostate-specific antigen and thyroglobulin are the most specific. The purpose of this article is to discuss the use of electron microscopy and immunohistochemistry in the site-specific diagnosis of metastatic adenocarcinomas of unknown primary origin. HUM PATHOL 29:1393-1402. Copyright (C) 1998 by W.B. Saunders Company.
引用
收藏
页码:1393 / 1402
页数:10
相关论文
共 50 条
  • [21] ADENOCARCINOMA OF UNKNOWN ORIGIN IN A PATIENT WITH PRIMARY INTESTINAL LYMPHANGIECTASIA
    MONTALBAN, C
    RODRIGUEZGARCIA, JL
    NOCITO, M
    FOGUE, L
    GARCIAGONZALEZ, R
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 1992, 15 (01) : 77 - 79
  • [22] ADENOCARCINOMA OF UNKNOWN PRIMARY ORIGIN - IMPACT OF CHEMOTHERAPY ON SURVIVAL
    INDUPALLI, SR
    BEDIKIAN, AY
    BODEY, GP
    SOUTHERN MEDICAL JOURNAL, 1981, 74 (12) : 1431 - 1435
  • [23] ADENOCARCINOMA OF UNKNOWN PRIMARY ORIGIN - TREATMENT WITH VINDESINE AND DOXORUBICIN
    FIORE, JJ
    KELSEN, DP
    GRALLA, RJ
    CASPER, ES
    MAGILL, G
    CHENG, E
    OCHOA, M
    CANCER TREATMENT REPORTS, 1985, 69 (06): : 591 - 594
  • [24] Obturator mononeuropathy due to adenocarcinoma of unknown primary origin
    Turkoglu, R.
    Gencer, M.
    Aker, F. V.
    Meric, K.
    Gokceer, S. Y.
    Coban, A.
    Tuzun, E.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2016, 37 (06) : 882 - 883
  • [25] COMBINATION CHEMOTHERAPY IN THE TREATMENT OF ADENOCARCINOMA OF UNKNOWN PRIMARY ORIGIN
    WALACH, N
    HORN, Y
    CANCER TREATMENT REPORTS, 1987, 71 (06): : 605 - 607
  • [26] CAPRID SYNDROME (METASTATIC CARCINOMA OF UNKNOWN PRIMARY ORIGIN)
    RIVAROLA, EG
    MORGENFELD, EL
    GERCOVICH, FG
    PRENSA MEDICA ARGENTINA, 1986, 73 (04): : 159 - 161
  • [27] Treatment of Regional Metastatic Melanoma of Unknown Primary Origin
    van Beek, Elke J. A. H.
    Balm, Alfons J. M.
    Nieweg, Omgo E.
    Hamming-Vrieze, Olga
    Lohuis, Peter J. F. M.
    Klop, W. Martin C.
    CANCERS, 2015, 7 (03): : 1543 - 1553
  • [28] ADENOCARCINOMA OF UNKNOWN ORIGIN
    MOERTEL, CG
    ANNALS OF INTERNAL MEDICINE, 1979, 91 (04) : 646 - 647
  • [29] ADENOCARCINOMA OF UNKNOWN ORIGIN
    NEILAN, BA
    CA-A CANCER JOURNAL FOR CLINICIANS, 1983, 33 (04) : 237 - 241
  • [30] Classification of metastatic adenocarcinoma of known and unknown primary using the cupprinttm
    Horlings, Hugo M.
    De Jong, D.
    Kerst, J. M.
    Helgason, H. H.
    Warmoes, M.
    Wesseling, J.
    Stork-Sloots, L. M.
    van't Veer, L. J.
    ANNALS OF ONCOLOGY, 2006, 17 : 246 - 246